What is the price target for CELL stock?
11 analysts have analysed CELL and the average price target is 1.53 USD. This implies a price increase of 53.29% is expected in the next year compared to the current price of 0.9981.
PHENOMEX INC (CELL) Forecast, Price Target & Analyst Ratings
NASDAQ:CELL • US0843101017
Current stock price
0.9981 USD
+0 (+0.31%)
At close:
0.999 USD
+0 (+0.09%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PHENOMEX INC (CELL).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Nov 6, 2023
- Period
- Q3 / 2023
- EPS Estimate
- -$0.24
- Revenue Estimate
- 19.964M
Price Target Details & History
Consensus Price Target and Range
Mean target
$1.53
Upside
+ 53.29%
From current price of $1.00 to mean target of $1.53, Based on 11 analyst forecasts
Low
$1.01
Median
$1.02
High
$3.15
Price Target Revisions
1 Month
0.00%
3 Months
-73.53%
Price Target Summary
11 Wall Street analysts provided a forecast for the next 12 months for CELL. The average price target is 1.53 USD. This implies a price increase of 53.29% is expected in the next year compared to the current price of 0.9981.
The average price target has been revised downward by 73.53% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
50.91%
CELL was analyzed by 11 analysts. The buy percentage consensus is at 51. So analysts seem to be rather neutral about CELL.
In the previous month the buy percentage consensus was at a similar level.
CELL was analyzed by 11 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-08-23 | TD Cowen | Downgrade | Outperform -> Market Perform |
| 2023-08-22 | Berenberg | Downgrade | Buy -> Hold |
| 2023-08-18 | Morgan Stanley | Upgrade | Underweight -> Equal-Weight |
| 2023-05-12 | Stifel | Maintains | Hold |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Nov 6, 2023
- Period
- Q3 / 2023
- EPS Estimate
- -$0.24
- Revenue Estimate
- 19.964M
- Revenue Q2Q
- -6.71%
- EPS Q2Q
- 25.09%
- Number of Analysts
- 7
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
CELL is expected to report earnings on 11/6/2023. The consensus EPS estimate for the next earnings is -0.24 USD and the consensus revenue estimate is 19.96M USD.
Full Analyst Estimates 2023 - 2026
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 64.3M 13.42% | 85.39M 32.80% | 78.6M -7.95% | 78.029M -0.73% | 104.06M 33.36% | 135.93M 30.63% | 182.58M 34.32% | |
| EBITDA YoY % growth | -35.29M -201.62% | -65.19M -84.73% | -85.54M -31.22% | -78.23M 8.55% | -39.234M 49.85% | -28.764M 26.69% | N/A | |
| EBIT YoY % growth | -40.39M -144.20% | -70.79M -75.27% | -94.54M -33.55% | -91.213M 3.52% | -53.079M 41.81% | -44.166M 16.79% | N/A | |
| Operating Margin | -62.81% | -82.90% | -120.28% | -116.90% | -51.01% | -32.49% | N/A | |
| EPS YoY % growth | N/A | -1.07 5.78% | -1.43 -33.64% | -1.17 17.97% | -0.60 49.04% | -0.28 52.56% | -0.28 2.88% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 23 | Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.24 25.09% | -0.21 49.00% | -0.19 37.48% | -0.17 49.00% | -0.14 42.55% | -0.10 53.66% | -0.13 31.58% | -0.10 41.18% | -0.06 55.56% | -0.04 57.89% |
| Revenue Q2Q % growth | 19.964M -6.71% | 23.154M 29.79% | 20.388M 10.09% | 21.594M 53.58% | 25.361M 27.03% | 29.59M 27.80% | 27.54M 35.08% | 29.682M 37.45% | 33.864M 33.53% | 36.516M 23.41% |
| EBITDA Q2Q % growth | -21.687M -56.02% | -18.274M -0.19% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -23.684M -15.65% | -20.655M 24.17% | -18.617M 13.57% | -15.9M 46.21% | -10.635M 55.10% | -5.496M 73.39% | -12.095M 35.03% | -9.554M 39.91% | -5.399M 49.23% | -3.155M 42.59% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
21.68%
EPS Next 5 Year
15.95%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
15.99%
Revenue Next 5 Year
20.33%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
18.40%
EBIT Next 5 Year
N/A
PHENOMEX INC / CELL Forecast FAQ
What is the next earnings date for CELL stock?
PHENOMEX INC (CELL) will report earnings on 2023-11-06, after the market close.
What are the consensus estimates for PHENOMEX INC (CELL) next earnings?
The consensus EPS estimate for the next earnings of PHENOMEX INC (CELL) is -0.24 USD and the consensus revenue estimate is 19.96M USD.
How do analysts rate PHENOMEX INC (CELL)?
The consensus rating for PHENOMEX INC (CELL) is 50.9091 / 100 . This indicates that analysts generally have a neutral outlook on the stock.